

Monoclonal Antibody Panel, Anti-Influenza A Virus H9 Hemagglutinin (HA) Protein

Catalog No. NR-9691

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

St. Jude Children's Research Hospital (CEIRS)

Product Description:

The monoclonal antibody panel, NR-9691, consists of six monoclonal antibodies (MAbs)¹⁻⁴: 1) G9-25, G1-26 and 1073-9 directed against the hemagglutinin (HA) protein of influenza A virus, A/chicken/Hong Kong/G9/1997 (H9N2),⁵ A/quail/Hong Kong/G1/1997 (H9N2),⁵ and A/Hong Kong/1073/1999 (H9N2)⁶, respectively, and 2) MAbs 15F1, 18G4 and 2F4 directed against the HA of influenza A virus A/duck/Hong Kong/Y280/1997 (H9N2)⁵ (see Table 1). All monoclonal antibodies were produced in mouse ascites. Ascites formation was induced by injecting cultured hybridoma cells into the peritoneal cavity of BALB/c mice that had been primed with Incomplete Freund's adjuvant. Antibody-rich ascites fluid was aseptically harvested 1 to 2 weeks following hybridoma cell injection. The harvested ascites fluid was pooled and then clarified using centrifugation and filtration. Sodium azide (0.02%) and gentamycin (0.01%) were added to the pooled ascites fluid prior to vialing and lyophilization.

Table 1		
BEI Resources #	MAbs	Antibody Class
NR-9482	G9-25	IgG2a.k, IgA.k
NR-9485	G9-26	IgG1.k
NR-9488	1073-9	IgG1a.k, IgM.k
NR-9491	15F1	IgG2b.k
NR-9494	18G4	IgG2b.k
NR-9497	2F4	IgG2b.k

Note: The hybridoma used to prepare NR-9482 and NR-9488 preparation may not be monoclonal and/or the preparation may contain endogenous murine immunoglobulin.

All six MAbs are available individually by ordering the indicated BEI Resources #.

Material Provided:

Each vial contains lyophilized (0.2 mL containing 0.02% sodium azide and 0.01% gentamycin) mouse ascites fluid.

Packaging/Storage:

This product was packaged in glass serum vials with an aluminum crimp seal. The product is provided frozen and should be stored at -20°C to -40°C immediately upon arrival. **Storage at warmer temperatures is not recommended due to a low bioburden.** At colder temperatures, the rubber stopper may become brittle and compromise the seal. **Each vial should be reconstituted with 0.2 mL of sterile distilled water.** Reconstituted material should be stored at -20°C to -40°C. Reconstituted material may be thawed at room temperature and should be re-frozen.

Functional Activity:

All six monoclonal antibodies are specific for the H9 HA subtype of the influenza A virus as determined in standard hemagglutination inhibition (HI) assays. In addition also demonstrates reactivity within the H9 HA subtype. HI titers with 20 different influenza strains of the H9 HA subtype representing Eurasian and North America lineages, as well as H9 HA viruses from other geographic areas, are shown on the Certificate of Analysis. No reactivity was observed with several viruses of North American lineage.

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Antibody Panel, Anti-Influenza A Virus H9 Hemagglutinin (HA) Protein, NR-9691."

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Xu, K. M., et al. "Evolution and Molecular Epidemiology of H9N2 Influenza A Viruses from Quail in Southern China, 2000 to 2005." *J. Virol.* 81 (2007): 2635-2645. PubMed: 17192315.
2. Butt, K. M., et al. "Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003." *J. Clin. Microbiol.* 43 (2005): 5760-5767. PubMed: 16272514.
3. Choi, Y. K., et al. "Continuing Evolution of H9N2 Influenza Viruses in Southeastern China." *J. Virol.* 78 (2004): 8609-8614. PubMed: 15280470.
4. Kaverin, N. V., et al. "Structural Differences among Hemagglutinins of Influenza A Virus Subtypes are Reflected in Their Antigenic Architecture: Analysis of H9 Escape Mutants." *J. Virol.* 78 (2004): 240-249. PubMed: 14671105.
5. Guan, Y., et al. "Molecular Characterization of H9N2 Influenza Viruses: Were They the Donors of the "Internal" Genes of H5N1 Viruses in Hong Kong?" *Proc. Natl. Acad. Sci. U. S. A.* 96 (1999): 9363-9367. PubMed: 10430948. GenPept: AAF00701, AAF00704, AAF00706.
6. Lin, Y. P., et al. "Avian-to-Human Transmission of H9N2 Subtype Influenza A Viruses: Relationship Between H9N2 and H5N1 Human Isolates." *Proc. Natl. Acad. Sci. U. S. A.* 97 (2000): 9654-9658. PubMed: 10920197. GenPept: CAB95856.
7. Chen, H., et al. "Generation and Characterization of an H9N2 Cold-Adapted Reassortant as a Vaccine Candidate." *Avian Dis.* 47 (2003): 1127-1130. PubMed: 14575127.
8. Atmar, R. L., et al. "Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations." *Clin. Infect. Dis.* 43 (2006): 1135-1142. PubMed: 17029131.
9. Liu, J., et al. "H9N2 Influenza Viruses Prevalent in Poultry in China are Phylogenetically Distinct from

A/quail/Hong Kong/G1/97 Presumed to be the Donor of the Internal Protein Genes of the H5N1 Hong Kong/97 Virus." *Avian Pathol.* 32 (2003): 551-560. PubMed: 14522712.

10. Guo, Y. J., et al. "Characterization of the Pathogenicity of Members of the Newly Established H9N2 Influenza Virus Lineages in Asia." *Virology* 267 (2000): 279-288. PubMed: 10662623.
11. Chen, H., et al. "Generation and Characterization of a Cold-Adapted Influenza A H9N2 Reassortant as a Live Pandemic Influenza Virus Vaccine Candidate." *Vaccine* 21 (2003): 4430-4436. PubMed: 14505926.
12. Chen, H., et al. "Generation and Evaluation of a High-Growth Reassortant H9N2 Influenza A Virus as a Pandemic Vaccine Candidate." *Vaccine* 21 (2003): 1974-1979. PubMed: 12706686.
13. Guan, Y., et al. "H9N2 Influenza Viruses Possessing H5N1-Like Internal Genomes Continue to Circulate in Poultry in Southeastern China." *J. Virol.* 74 (2000): 9372-9380. PubMed: 11000205.
14. Saito, T., W. Lim. and M. Tashiro. "Attenuation of a Human H9N2 Influenza Virus in Mammalian Host by Reassortment with an Avian Influenza Virus." *Arch. Virol.* 149 (2004): 1397-1407. PubMed: 15221539.
15. Saito, T., et al. "Characterization of a Human H9N2 Influenza Virus Isolated in Hong Kong." *Vaccine* 20 (2001): 125-133. PubMed: 11567756.
16. Li, K. S., et al. "Characterization of H9 Subtype Influenza Viruses from the Ducks of Southern China: A Candidate for the Next Influenza Pandemic in Humans?" *J. Virol.* 77 (2003): 6988-6994. PubMed: 12768017.
17. Stephenson, I., et al. "Safety and Antigenicity of Whole Virus and Subunit Influenza A/Hong Kong/1073/99 (H9N2) Vaccine in Healthy Adults: Phase I Randomised Trial." *Lancet* 362 (2003): 1959-1966. PubMed: 14683655.
18. Pushko, P., et al. "Influenza Virus-Like Particles Comprised of the HA, NA, and M1 Proteins of H9N2 Influenza Virus Induce Protective Immune Responses in BALB/c Mice." *Vaccine* 23 (2005): 5751-5759. PubMed: 16143432.
19. Pushko, P., et al. "Evaluation of Influenza Virus-Like Particles and Novasome Adjuvant as Candidate Vaccine for Avian Influenza." *Vaccine* 25 (2007): 4283-4290. PubMed: 17403562.
20. Cong, Y. L., et al. "Antigenic and Genetic Characterization of H9N2 Swine Influenza Viruses in China." *J. Gen. Virol.* 88 (2007): 2035-2041. PubMed: 17554038.
21. Wang, S., et al. "Genetic Analysis of the Nonstructural (NS) Genes of H9N2 Chicken Influenza Viruses Isolated in China During 1998-2002." *Virus Genes* 31 (2005): 329-335. PubMed: 16175338.

ATCC® is a trademark of the American Type Culture Collection.

